» Articles » PMID: 22153828

Diagnosis and Treatment Status of Migraine: a Clinic-based Study in China

Overview
Journal J Neurol Sci
Publisher Elsevier
Specialty Neurology
Date 2011 Dec 14
PMID 22153828
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To investigate the prevalence and clinical characteristics of migraine, and to evaluate the current status of migraine diagnosis and treatment in neurological outpatients.

Methods: A face-to-face interview survey was conducted in the neurological clinic of a tertiary care hospital during a period of three months. A headache questionnaire for patients who consulted doctors with a chief complaint of headache was completed by a qualified and experienced physician in headache studies during the interview. Migraine diagnosis was made by physicians based on the criteria of the second edition of the International Classification of Headache Disorders.

Results: Of 9282 patients assessed, 19.5% (1806) complained of headache. The prevalence of migraine was 23.8%(401/1683)among headache patients. The average age of migraineurs was 42.2±13.1 years and 80.5% were female. Of all migraineurs, 68.6% had consulted a physician for headache in the previous one year, and only 13.5% had received a physician diagnosis of migraine. A total of 173 migraine patients (43.1%) had not taken any analgesic for acute treatment in the previous three months and only 11 migraineurs (2.7%) had used preventative medications. Medication overuse was significantly more common in male than in female patients with migraine (P<0.01).

Conclusions: Migraine is the most common headache disorder in the neurological clinic and it remains underrecognized and undertreated in China. Public health initiatives to improve diagnosis and treatment of migraine are needed.

Citing Articles

Clinical decision support system using hierarchical fuzzy diagnosis model for migraine and tension-type headache based on International Classification of Headache Disorders, 3rd edition.

Yin Z, Li H, Han X, Ran Y, Wang Z, Dong Z Front Neurol. 2024; 15:1444197.

PMID: 39318875 PMC: 11420035. DOI: 10.3389/fneur.2024.1444197.


Healthcare utilisation and economic burden of migraines among bank employees in China: a probabilistic modelling study.

Wei D, Wong L, He X, Loganathan T J Headache Pain. 2024; 25(1):60.

PMID: 38641794 PMC: 11027248. DOI: 10.1186/s10194-024-01763-w.


Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.

Yu S, Guo A, Wang Z, Liu J, Tan G, Yang Q J Headache Pain. 2024; 25(1):57.

PMID: 38627638 PMC: 11020209. DOI: 10.1186/s10194-024-01731-4.


Status of diagnosis and preventative treatment for primary headache disorders: real-world data of unmet needs in China.

Liu H, Dong M, Liu K, Jia Z, Gui W, Cheng Y J Headache Pain. 2023; 24(1):119.

PMID: 37653478 PMC: 10472552. DOI: 10.1186/s10194-023-01654-6.


Telemedicine efficacy and satisfaction of patients and headache specialists in migraine management.

Liu Q, Liu F, Yu X, Zang J, Tan G Front Mol Neurosci. 2023; 16:1093287.

PMID: 37033375 PMC: 10076524. DOI: 10.3389/fnmol.2023.1093287.